Related Experiment Video
Updated: Nov 6, 2025
07:40
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.4K
Should We Be Using Upstream Beta-Blocker Therapy for Acute Myocardial Infarction?
Georgios Giannakopoulos1, Stephane Noble2
1Cardiology Division, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland. georgios.giannakopoulos@hcuge.ch.
Current Cardiology Reports
|May 7, 2021
Summary
The benefit of administering beta-blockers before primary percutaneous coronary intervention (PCI) remains unclear. While early beta-blocker use is safe for stable patients, its impact on infarct size and mortality requires further investigation in large trials.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Early beta-blocker administration in animal models suggested reduced infarct size.
- Human studies yielded mixed results regarding infarct size and survival benefits.
Purpose of the Study:
- To review the current evidence on the timing of beta-blocker administration in relation to primary percutaneous coronary intervention (PCI).
- To assess the safety and efficacy of early versus deferred beta-blocker administration in acute myocardial infarction.
Main Methods:
- Review of animal studies and human clinical trials evaluating early intravenous beta-blocker administration post-myocardial infarction.
- Focus on studies conducted in the primary PCI era.
Main Results:
- Early intravenous beta-blockers are safe in hemodynamically stable patients and protect against malignant arrhythmias.
- Evidence regarding the impact of early beta-blockers on infarct size and mortality is equivocal.
- Only two studies in the primary PCI era evaluated pre-PCI beta-blocker administration.
Conclusions:
- Further large-scale, double-blind, randomized trials are necessary to definitively assess the benefits of early metoprolol injection in STEMI patients.
- The optimal timing for beta-blocker administration in STEMI patients undergoing primary PCI requires clarification.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
539
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
539
01:28Acute Coronary Syndrome IV: Interprofessional Care
72
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
72
01:14Myocarditis III: Medical Management
45
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
45
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
01:16Antianginal Drugs: Nitrates and β-Blockers
932
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
932
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
872
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
872